Characterization and Modification of Drug Glycosylation

Glycans play a key role in many major diseases. In order to help customers successfully carry out drug development projects, CD BioGlyco provides the most advanced pharmaceutical glycomic analysis platform to develop new drugs for glycosylation-related diseases, or make glycosylation changes to drugs to enhance their characteristics. We have the confidence to be your essential research assistant in the field of glycobiology.


Glycans are complex polymers composed of many monosaccharide molecules with covalent bonds. They are large in number and diverse in variety, decorating the surface of cells. Glycans are almost directly involved in all life activities of all organisms and play an important role in most human diseases. Although they are ubiquitous and important, glycans with complex structures and few regularities are still very mysterious to humans.

Glycans participate in major diseases such as autoimmune diseases and cancer. Many studies have reported that changes in cell surface glycans can lead to tumor cell metastasis; glycans can regulate the functions of many receptors, such as regulating the function of Notch receptors to affect many developmental events; Delete or expand on their relation with glycans?

At present, there are already some important glycan-related drugs on the market, such as hyaluronic acid for the treatment of arthritis; drugs Relenza and Tamiflu are structural analogs of sialic acid, which can inhibit the activity of influenza virus neuraminidase; natural heparin and synthetic heparin oligosaccharides are widely used clinically as anticoagulants; many recombinant drugs are glycoproteins, such as monoclonal antibodies, and their biological activities are closely related to their glycoforms. When the glycan glycoforms are incorrect, it may cause harmful immune response. The importance of glycobiology has been recognized, and more glycan-related drugs are gradually moving to the market.

Fig 1. Role of glycans in cancer development and progression (Cai, L.; et al. 2018)Fig 1. Role of glycans in cancer development and progression (Cai, L.; et al. 2018)

Characterization and Modification of Drug Glycosylation


CD BioGlyco uses advanced and unique technology platforms to conduct comprehensive glycosylation profiling on various biological samples and obtain a systematic analysis of the structure and function of biological drugs. We can help customers improve drug characteristics and optimize the new drug development process to explore the importance of glycomics in precision medicine.

  • We have the expertise in LC-MS, a large number of world-class technology platforms, and can fully characterize glycans according to customer needs.
  • We can process many different types of biological samples, including cells, plasma, saliva, etc.
  • We utilize AI technology to process samples with high-throughput screening and speed.
  • We have all kinds of glycan standards to complete the analysis in the most accurate way.


  • New drug development
  • Change drug glycosylation to enhance efficacy and safety
  • Biomarker recognition
  • Stratification of patients with specific diseases
  • Study on the structure and function of glycans

Advantages of Us

  • World-class technology platforms capable of processing various biological samples
  • Reliable and accurate results
  • Whole experiment is undertaken by a team of experts
  • High throughput and fast speed
  • Our experienced scientists have completed thousands of drug development projects

CD BioGlyco has established a comprehensive drug glycosylation characterization and modification platform to help customers explore the close relationship between glycosylation modification and precision medicine. CD BioGlyco has more than ten years of successful drug discovery and development experience. We can promptly provide you with potential research directions to ensure a successful start to your project.

Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.


  1. Dwek, R.A.; et al. Targeting glycosylation as a therapeutic approach. Nature Reviews Drug Discovery. 2002, 1(1): 65-75.
  2. Cai, L.; et al. Advances in glycosylation-mediated cancer-targeted drug delivery. Drug Discovery Today. 2018, 23(5): 1126-1138.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.